Germany Revises Pharmaceutical Discount Plans Amid Industry Pushback

Germany's government is scrapping its initial plan for variable pharmaceutical discounts due to industry opposition. The new directive aims for fixed discounts, allowing companies better financial planning. Meanwhile, discussions continue for a broader healthcare overhaul addressing a looming 20 billion euro funding gap.

Germany's government has decided to replace its plan for variable pharmaceutical discounts following industry concerns, a government insider revealed on Monday. Initially, the proposal would have required drug companies to offer varying price reductions based on national healthcare spending and revenue metrics.

The decision was made to introduce fixed discounts to ensure better financial predictability for companies, though specifics on the size of these fixed discounts remain undisclosed. While the federal health ministry has not finalized these changes, broader discussions about transforming Germany's statutory healthcare system continue. The aim is to bridge a 20 billion euro funding deficit and prevent an increase in mandatory health insurance premiums.

This initiative faced criticism from various stakeholders, including physician and patient advocacy groups, as well as drug industry leaders, who expressed concerns over potential impacts on investments. Eli Lilly's CEO, for instance, announced a significant cut to their investment plans in Germany. The VFA, representing innovative pharmaceutical companies, stressed the need for a detailed impact assessment, leaving further steps to the democratic process.